ApeX Therapeutics (United States)

Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic

Fenil Shah, Derek P. Logsdon, Richard A. Messmann et al. · npj Precision Oncology · 2017 · 157 citations · Full text

Medicine, Cancer Biology, Oncology +15

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

Nicholas Pulliam, Fang Fang, Ali Özeş et al. · Clinical Cancer Research · 2018 · 128 citations · Full text

Medicine, Oncology, Pharmacology +17

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

Ronald L. Van Heertum, Robert Scarimbolo, John G. Wolodzko et al. · Drug Design Development and Therapy · 2017 · 109 citations · Full text

Medicine, Nuclear Medicine, Oncology +13

Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy

Mark R. Kelley, James H. Wikel, Chunlu Guo et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson et al. · Clinical Cancer Research · 2014 · 56 citations

Medicine, Oncology, Pharmacology +17